24-week, open, randomized, crossover trial.Patients with NIDDM and secondary failure (fasting blood glucose > 7.8 mmol/l and HbA1c >25% above the upper limit). All patients were treated with OHAs and diet for at least 1 year before entering the study. The trial consisted of two 12-week periods of insulin administration. Group A started with NovoPen® 3 in Period 1 and crossed over to syringe/vial use in Period 2. Group B followed the study in the inverse order. Here, INS is linked to type 2 diabetes mellitus.